News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

Novo's upcoming Alzheimer's trial results will test whether Rybelsus can slow cognitive decline and reshape treatment ...

Lilly’s (LLY) recent climb to reach a $1T market cap will come under scrutiny in the coming days when Novo Nordisk (NVO) ...

Compared with the lowest quintile of midlife physical activity, the top two quintiles were associated with 40% lower ...

The combination of a recently approved blood test for the detection of Alzheimer’s disease, combined with two medications that slow the progression of the disease, is drastically improving outcomes ...

Higher physical activity in midlife and late life is linked to a substantially lower risk of all-cause and Alzheimer’s ...

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering ...

Over the follow-up period, 13.2% (567) of the 4,290 participants developed dementia, mostly in the older age group. This is ...

New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for ...

The University of Central Florida's School of Performing Arts and College of Medicine are working together on an experiment ...